Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Multiple Cancer Types

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Lung, Small Cell
III
Iams, Wade
NCT03703297
VICCTHO1901

A Dose Escalation Study Of PF?06939999 In Participants With Advanced Or Metastatic Solid Tumors

Multiple Cancer Types

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
Bladder, Cervical, Esophageal, Head/Neck, Lung, Non Small Cell, Phase I, Uterine
I
Berlin, Jordan
NCT03854227
VICCPHI1909

Nivolumab and Vorolanib in Treating Patients with Non-Small Cell Lung Cancer and Refractory Thoracic Tumors

Multiple Cancer Types

This phase I / II trial studies the side effects and best dose of vorolanib when given in combination with nivolumab in treating patients with non-small cell lung cancer and thoracic tumors that aren't responding to treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vorolanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and vorolanib may work better in treating patients with non-small cell lung cancer and thoracic tumors.
Lung, Non Small Cell
I/II
Horn, Leora
NCT03583086
VICCTHO1802

Integrated Telehealth or In-Person Palliative Care in Improving Quality of Life in Patients with Advanced Non-small Cell Lung Cancer

Multiple Cancer Types

This randomized clinical trial studies how well integrated telehealth or in-person palliative care works in improving quality of life in patients with non-small lung cancer that has spread to other places in the body. Early involvement in palliative care may lesson many of the distressing physical and emotional symptoms and help patients and their families cope with serious illness as well as improve patients’ and their loved ones’ experience with cancer. Integrated telehealth palliative care involves patients meeting with palliative care clinicians using secure video-conferencing technology. It is not yet known whether giving integrated telehealth or in-person palliative care works better for patients and their families in improving quality of life.
Lung, Non Small Cell
N/A
Martin, Sara
NCT03375489
VICCTHO1839

Ifetroban in Treating Patients with Malignant Solid Tumors at High Risk of Metastatic Recurrence

Multiple Cancer Types

This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment (recurrent) and spreading throughout the body (metastatic). Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.
Breast, Esophageal, Gastric/Gastroesophageal, Lung, Non Small Cell, Pancreatic, Small Cell
II
Mayer, Ingrid
NCT03694249
VICCMD1854

LIBERTI: Role of Circulating Tumor DNA (ctDNA) from LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation

Multiple Cancer Types

Lung, Non Small Cell, Phase I
N/A
Massion, Pierre
VICCTHO1868

Pulmonary Physiology and Systemic Inflammatory Signature Investigations in Early Onset Pulmonary Events Associated with Brigatinib Use in Non-Small Cell Lung Cancerl and Other Diseases

Multiple Cancer Types

Lung, Non Small Cell
II
Horn, Leora
NCT03389399
VICCTHO1885

Nashville Biosciences Blood Sample Collection Study

Multiple Cancer Types

Colon, Liver, Lung, Non Small Cell, Ovarian, Pancreatic, Rectal
N/A
Bernard, Gordon
VICCMD18123

Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Multiple Cancer Types

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).
Lung, Non Small Cell
II
Horn, Leora
NCT03539536
VICCTHO18125

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Lung

The study will evaluate M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor expression.
Lung
II
Iams, Wade
NCT03631706
VICCTHO18139

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: